129 related articles for article (PubMed ID: 30316146)
1. Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma.
Zakharia K; Miyabe K; Wang Y; Wu D; Moser CD; Borad MJ; Roberts LR
Transl Oncol; 2019 Jan; 12(1):143-153. PubMed ID: 30316146
[TBL] [Abstract][Full Text] [Related]
2. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
[TBL] [Abstract][Full Text] [Related]
3. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
[TBL] [Abstract][Full Text] [Related]
4. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Siddiqui-Jain A; Bliesath J; Macalino D; Omori M; Huser N; Streiner N; Ho CB; Anderes K; Proffitt C; O'Brien SE; Lim JK; Von Hoff DD; Ryckman DM; Rice WG; Drygin D
Mol Cancer Ther; 2012 Apr; 11(4):994-1005. PubMed ID: 22267551
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin inhibits growth of cholangiocarcinoma cells.
Okada T; Sawada T; Kubota K
Hepatogastroenterology; 2009; 56(89):6-10. PubMed ID: 19453019
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo.
Xu D; Ma Y; Zhao B; Li S; Zhang Y; Pan S; Wu Y; Wang J; Wang D; Pan H; Liu L; Jiang H
Oncol Rep; 2014 May; 31(5):2063-70. PubMed ID: 24603952
[TBL] [Abstract][Full Text] [Related]
7. Sequence of CX-4945 and Cisplatin Administration Determines the Effectiveness of Drug Combination and Cellular Response in Cholangiocarcinoma Cells
Lertsuwan J; Sawasdichai A; Tasnawijitwong N; Gaston K; Jayaraman PS; Satayavivad J
Anticancer Res; 2021 Dec; 41(12):6155-6167. PubMed ID: 34848470
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
9. Flavokawain B Inhibits Growth of Cholangiocarcinoma Cells by Suppressing the Akt Pathway.
Son JH; Choi YH; Lee SH; Paik WH; Ryu JK; Kim YT
In Vivo; 2023; 37(3):1077-1084. PubMed ID: 37103099
[TBL] [Abstract][Full Text] [Related]
10. Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Hu MH; Huang TT; Chao TI; Chen LJ; Chen YL; Tsai MH; Liu CY; Kao JH; Chen KF
Liver Int; 2018 Dec; 38(12):2248-2259. PubMed ID: 29797403
[TBL] [Abstract][Full Text] [Related]
11. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism.
Lertsuwan J; Lertsuwan K; Sawasdichai A; Tasnawijitwong N; Lee KY; Kitchen P; Afford S; Gaston K; Jayaraman PS; Satayavivad J
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30142881
[TBL] [Abstract][Full Text] [Related]
12. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.
Ke F; Wang Z; Song X; Ma Q; Hu Y; Jiang L; Zhang Y; Liu Y; Zhang Y; Gong W
Drug Des Devel Ther; 2017; 11():1753-1766. PubMed ID: 28670110
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
14. LYG-202 augments tumor necrosis factor-α-induced apoptosis via attenuating casein kinase 2-dependent nuclear factor-κB pathway in HepG2 cells.
Chen FH; Lu N; Zhang HW; Zhao L; He LC; Sun HP; You QD; Li ZY; Guo QL
Mol Pharmacol; 2012 Nov; 82(5):958-71. PubMed ID: 22909797
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
16. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
17. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
18. Repurposing cimetidine for cholangiocarcinoma: Antitumor effects
Dana P; Vaeteewoottacharn K; Kariya R; Matsuda K; Wongkham S; Okada S
Oncol Lett; 2017 Mar; 13(3):1432-1436. PubMed ID: 28454273
[TBL] [Abstract][Full Text] [Related]
19. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S
Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
